<DOC>
	<DOCNO>NCT01550185</DOCNO>
	<brief_summary>The purpose study find high safe dose examine side effect effectiveness eltrombopag olamine patient acute myeloid leukemia ( AML ) treat chemotherapy respond previous therapy suffer relapse</brief_summary>
	<brief_title>Eltrombopag Olamine Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) examine tolerability daily oral eltrombopag ( eltrombopag olamine ) ( 14 day +/- 2 day initiation cytarabine ) patient receive high dose cytarabine mitoxantrone treatment acute myeloid leukemia patient hypoplastic bone marrow 14 day +/- 2 day initiation cytarabine . II . To examine platelet count recovery &gt; = 100 x 10^9/L eltrombopag administer follow high dose cytarabine mitoxantrone treatment acute myeloid leukemic patient . OUTLINE : This dose-escalation study . Patients receive eltrombopag olamine orally ( PO ) daily ( QD ) day 1 day 62 . Treatment continue 9 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<criteria>Relapsed/refractory AML patient receive standard care cytarabine mitoxantrone chemotherapy regimen Patients must either Grade 4 thrombocytopenia ( platelet count &lt; 25 x 10^9/L ) due chemotherapy unless transfusion within 2472 hour Current systemic treatment AML , exception granulocyte colonystimulating factor ( GCSF ) must discontinue least 7 day prior entry study ; addition : At least 4 week Day 1 interleukin ( IL ) 11 ( oprelvekin ) At least 8 week Day 1 antithymocyte/antilymphocyte globulin Patients prior stem cell transplant ( SCT ) must fail SCT Patients must document hypoplasia bone marrow aspiration biopsy 14 day +/ 2 day initiation cytarabine treatment schedule ( define &lt; 5 % blast &lt; 20 % cellularity ) Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status = &lt; 2 Patient able understand comply protocol requirement instruction Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) except Gilbert syndrome case clearly indicative inadequate organ function , i.e. , elevation indirect ( hemolytic ) bilirubin absence alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) abnormality ALT AST = &lt; 3 x ULN Creatinine = &lt; 1.5 x ULN Patient practice acceptable method contraception ( documented chart ) ; female patient ( female partner male patient ) must either nonchildbearing potential ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation postmenopausal &gt; 1 year ) , childbearing potential use 1 follow highly effective method contraception ( i.e. , Pearl Index &lt; 1.0 % ) 2 week prior administration study medication , throughout study , 28 day completion premature discontinuation study : Complete abstinence intercourse Intrauterine device ( IUD ) Two form barrier contraception ( diaphragm plus spermicide , male condom plus spermicide ) Male partner sterile prior entry study partner female Systemic contraceptive ( combine progesterone ) Demonstrate ability swallow retain oral medication Patient legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure Patients diagnosis acute promyelocytic leukemia Patients QTcF &gt; 450 msec ( QTcF &gt; 480 msec patient Bundle Branch Block ) AML patient persistent disease recent treatment define &gt; 5 % blast and/or &gt; 20 % cellularity report persistent residual disease pathological report patient 's bone marrow biopsy 14 day +/ 2 day initiation cytarabine Patients know thrombophilic risk factor ; exception : patient potential benefit participate study outweigh potential risk thromboembolic event , determine investigator Current alcohol drug abuse Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication Active uncontrolled infection Patients know active hepatitis B , hepatitis C , seropositive human immunodeficiency virus ( HIV ) ; test require absence clinical suspicion Patients liver cirrhosis ( determined investigator ) Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate eltrombopag excipient contraindicate patient ' participation Patients East Asian ancestry ( i.e. , Chinese , Japanese , Taiwanese , Korean ) Patients preexist cardiovascular disease ( include congestive heart failure , New York Heart Association [ NYHA ] Grade IIIIV ) , arrhythmia know increase risk thromboembolic event ( e.g. , atrial fibrillation ) Unwilling unable follow protocol requirement Any condition , Investigator 's opinion , deem patient unsuitable candidate receive study drug No aspirin ( ASA ) nonsteroidal antiinflammatory drug ( NSAIDS ) administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>